In U.S. Market, Small Indian Drug Firms Turn Up The Heat On Their Big Brothers
This article was originally published in PharmAsia News
Smaller Indian companies are gaining ground in the U.S. market and catching up to their Indian big brothers – some are even proving a threat to them.
You may also be interested in...
Proposed and existing user fees would fund 44% of the $4.5 billion FDA FY 2013 spending plan. User fees are projected at $20 million for biosimilars and $229 million for generic drugs.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.